| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. |
| 臺大學術典藏 |
2022-09-15T01:08:59Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.; Chua K.L.M.; Chia-Chi Lin; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; Yang J.C.; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2022-09-15T01:08:48Z |
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium
|
Shimizu T.; Kim D.-W.; Loong H.H.; Chia-Chi Lin; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-08-10T02:37:43Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; CHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2022-06-27T07:00:11Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2022-06-27T06:59:36Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2021-11-03T05:24:54Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2021-04-23T05:56:32Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Chih-Hsin Yang;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Cheng J.C.-H.;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y.; Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; CHIH-HSIN YANG; Wang J.; Babu K.G.; Nakayama Y.; Alip A.; Chua K.L.M.; Cheng J.C.-H.; Senan S.; Ahn Y.C.; Kim T.-Y.; Ahn H.K.; Peters S.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.;Chua K.L.M.;Lin C.-C.;Lee V.H.F.;Tho L.M.;Chan A.W.;Ho G.F.;Reungwetwattana T.;Ychih-Hsin Yang;Kim D.-W.;Soo R.A.;Ahn Y.C.;Onishi H.;Ahn M.-J.;Mok T.S.K.;Tan D.S.W.;Yang F.; Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
|
Tan D.S.-W.;Leighl N.B.;Riely G.J.;Chih-Hsin Yang;Sequist L.V.;Wolf J.;Seto T.;Felip E.;Aix S.P.;Jonnaert M.;Pan C.;Tan E.Y.;Ko J.;Moody S.E.;Kim D.-W.; Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
|
Wu Y.-L.;Cheng Y.;Zhou J.;Lu S.;Zhang Y.;Zhao J.;Kim D.-W.;Soo R.A.;Kim S.-W.;Pan H.;Chen Y.-M.;Chian C.-F.;Liu X.;Tan D.S.W.;Bruns R.;Straub J.;Johne A.;Scheele J.;Park K.;Chih-Hsin Yang;Liu Z.;Chen X.;Wang M.;Yu S.;Zhang H.;Fang J.;Li W.;Yang C.-H.;Chang G.-C.;Hsia T.-C.;Yang C.-T.;Wang C.-C.;Cho B.C.;Lee K.H.;Kim Y.-C.;An H.J.;Woo I.S.;Cho J.Y.;Shin S.W.;Lee J.-S.;Kim J.-H.;Yoo S.S.;Kato T.;Shinagawa N.;Tan S.W.D.;Ngo L.S.-M.;Ratnavelu K.;Ahmad A.R.;Liam C.K.;De Marinis F.;Tassone P.;Molla A.I.;Calles Blanco A.;Lazaro Quintela M.E.;Felip Font E.;Dingemans A.-M.;Bui L.; Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 臺大學術典藏 |
2020-08-12T06:34:32Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Geater S.L.; Wolf J.; Paz-Ares L.; Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Soria J.-C.;Tan D.S.W.;Chiari R.;Wu Y.-L.;Paz-Ares L.;Wolf J.;Geater S.L.;Orlov S.;Cortinovis D.;Chong-Jen Yu;Hochmair M.;Cortot A.B.;Tsai C.-M.;Moro-Sibilot D.;Campelo R.G.;Mcculloch T.;Sen P.;Dugan M.;Pantano S.;Branle F.;Massacesi C.;De Castro G.;Jr; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2020-08-12T06:34:32Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Geater S.L.; Wolf J.; Paz-Ares L.; Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Soria J.-C.;Tan D.S.W.;Chiari R.;Wu Y.-L.;Paz-Ares L.;Wolf J.;Geater S.L.;Orlov S.;Cortinovis D.;Chong-Jen Yu;Hochmair M.;Cortot A.B.;Tsai C.-M.;Moro-Sibilot D.;Campelo R.G.;Mcculloch T.;Sen P.;Dugan M.;Pantano S.;Branle F.;Massacesi C.;De Castro G.;Jr; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos
|
Chang J.W.C; Alip A; Peters S; Douillard J.-Y.; Soo R.A; Park K; Mitsudomi T; Azrif M; CHIH-HSIN YANG; Tan D.S.W; Kim D.-W; Wu Y.-L;Planchard D;Lu S;Sun H;Yamamoto N;Kim D.-W;Tan D.S.W;Chih-Hsin Yang;Azrif M;Mitsudomi T;Park K;Soo R.A;Chang J.W.C;Alip A;Peters S;Douillard J.-Y.; Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos
|
Chang J.W.C; Alip A; Peters S; Douillard J.-Y.; Soo R.A; Park K; Mitsudomi T; Azrif M; CHIH-HSIN YANG; Tan D.S.W; Kim D.-W; Wu Y.-L;Planchard D;Lu S;Sun H;Yamamoto N;Kim D.-W;Tan D.S.W;Chih-Hsin Yang;Azrif M;Mitsudomi T;Park K;Soo R.A;Chang J.W.C;Alip A;Peters S;Douillard J.-Y.; Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi F; Drilon A; De Braud F; Cho B.C; Ahn M.J; Siena S; Krebs M.G; Chia-Chi Lin; John T; Tan D.S.W; Seto T; Dziadziuszko R; Arkenau H.-T; Rolfo C; Wolf J; Ye C; Riehl T; Eng S; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2020 |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Yang F.; Tan D.S.W; Mok T.S.K; Ahn M.-J; Onishi H; Ahn Y.C; Soo R.A; Kim D.-W; Yang J.C; Reungwetwattana T; Ho G.F; Yang F.;Tan D.S.W;Mok T.S.K;Ahn M.-J;Onishi H;Ahn Y.C;Soo R.A;Kim D.-W;Yang J.C;Reungwetwattana T;Ho G.F;Chan A.W;Tho L.M;Lee V.H.F;Chia-Chi Lin;Chua K.L.M;Tan W.L; Tan W.L; Chua K.L.M; Chia-Chi Lin; Lee V.H.F; Tho L.M; Chan A.W |
